Patient demographics and characteristics
| Primary PD-(L)1 resistance (N=28) | Acquired PD-(L)1 resistance (N=30) | |
| Age median (range), years | 67.6 (49.7–89.8) | 67.8 (46.6–84.0) |
| Male | 18 (64) | 18 (60) |
| Race | ||
| White | 24 (86) | 26 (87) |
| Black | 3 (11) | 3 (10) |
| Native American | 1 (3) | 0 (0) |
| Not reported | 0 (0) | 1 (3) |
| Hispanic ethnicity | 1 (4) | 3 (10) |
| No of prior lines of therapy for stage IV disease | ||
| <2 | 9 (32) | 12 (40) |
| ≥2 (max 4) | 19 (68) | 18 (60) |
| Median (range) PFS on prior anti-PD-(L)1 therapy, months | 3.0 (1.4–5.5) | 10.0 (5.6–30.4) |
| Best response to prior anti-PD-(L)1 therapy | ||
| Complete response* | 0 (0) | 3 (10) |
| Partial response* | 2 (7) | 7 (23) |
| Stable disease | 11 (39) | 20 (67) |
| Progressive disease | 15 (54) | 0 (0) |
| Performance status | ||
| 0 | 7 (25) | 10 (33) |
| 1 | 21 (75) | 20 (67) |
| Smoking status | ||
| Current smoker | 10 (36) | 10 (33) |
| Former smoker | 17 (61) | 19 (63) |
| Never smoker | 1 (4) | 1 (3) |
| Weight loss ≥10% | 2 (8) | 2 (7) |
| PD-L1 expression† (TPS (%)) | ||
| <1% | 10 (36) | 3 (10) |
| 1%–49% | 5 (18) | 9 (30) |
| 50% | 5 (18) | 2 (7) |
| Unknown | 8 (28) | 16 (53) |
| Tumor mutational burden | ||
| <10 mt/Mb | 8 (28) | 11 (37) |
| ≥10 mt/Mb | 17 (61) | 17 (57) |
| Not evaluable | 3 (11) | 2 (6) |
Values are shown as n (%) unless otherwise stated.
*Includes confirmed and unconfirmed responses per investigator assessment.
†PD-L1 expression was assessed by immunohistochemistry on tumor samples using 22C3 pharmDx assay (Agilent Technologies, Santa Clara, California, USA).
PD-L1, programmed death ligand 1; TPS, Tumor Proportion Score.